InterCure Ltd. (NASDAQ:INCR - Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 27,400 shares, a decrease of 33.3% from the January 31st total of 41,100 shares. Approximately 0.1% of the company's shares are short sold. Based on an average daily trading volume, of 32,700 shares, the days-to-cover ratio is presently 0.8 days.
InterCure Stock Performance
INCR traded up $0.06 during trading on Wednesday, reaching $1.63. 62,152 shares of the stock traded hands, compared to its average volume of 42,432. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.15 and a current ratio of 1.78. The stock's 50-day moving average is $1.65 and its 200 day moving average is $1.69. InterCure has a 12 month low of $1.17 and a 12 month high of $3.72.
Institutional Investors Weigh In On InterCure
A number of hedge funds have recently added to or reduced their stakes in INCR. Jane Street Group LLC bought a new stake in shares of InterCure during the third quarter valued at approximately $49,000. Virtu Financial LLC acquired a new stake in InterCure in the 3rd quarter valued at $43,000. Finally, Moore Capital Management LP bought a new stake in InterCure during the 4th quarter valued at $156,000. 8.34% of the stock is currently owned by institutional investors.
About InterCure
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Featured Articles
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
